← Back to patent-cliff list
HRS-2189
Tier C — Watch / tradeHRS-2189
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KAT6B
Indications (approved)：Colorectal cancer, Breast cancer, Prostate cancer, Solid tumour
Regional status
US
-
EU
-
China
Phase II
2024-12-31
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of HRS-2189?
Approved indications include: Colorectal cancer, Breast cancer, Prostate cancer, Solid tumour.
When does the HRS-2189 patent expire?
No public expiry year is available for HRS-2189 yet; this page updates once verified.
How do I get a quote for HRS-2189 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01